MARKET INTELLIGENCE·M&A
Altaris Acquires Simulations Plus for $375M: Reshaping Computational Drug Discovery Landscape
Altaris has agreed to acquire Simulations Plus for approximately $375 million, taking the computational drug discovery software firm private. This strategic move aims to combine Simulations Plus with Altaris's existing portfolio company, Chemical Computing Group, creating a more integrated platform. This consolidation will significantly impact pharmaceutical R&D, supply chain strategies, and the competitive landscape for in silico drug development tools.
90-Day Activity
Simulations Plus
RARobert Ashworth· Principal Intelligence Analyst8h ago